Results 91 to 100 of about 193,702 (280)

ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib

Frontiers in Oncology
ObjectiveTo assess the influence of F1174S mutation on kinase activity and drug sensitivity of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion (EML4-ALK) variants 1 and 3.MethodsWe constructed mammalian expression plasmids of both wildtype and F1174 mutant EML4-ALK variants 1 and 3, and then ...
Jikui Guan, Jikui Guan, Tzu-Po Chuang, Anders Vikström, Ruth H. Palmer, Bengt Hallberg   +5 more
openaire   +4 more sources

Local Specific IgE Levels Can Predict and Monitor the Therapeutic Response to Subcutaneous Immunotherapy With House Dust Mite

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Identifying predictive and monitoring biomarkers for allergen immunotherapy response is crucial for enhancing clinical efficacy. This study aims to investigate the systemic and local levels of immunoglobulins and identify potential biomarkers in house dust mite (HDM) allergic rhinitis (AR) patients who are undergoing subcutaneous ...
Xu Xu, Jingyun Li, Xu Zhang, Yu Song, Lin Xi, Luo Zhang, Yuan Zhang   +6 more
wiley   +1 more source

Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO2 emissions in Sweden

Scientific Reports
In Sweden, allergy immunotherapy (AIT) is available as either subcutaneous immunotherapy (SCIT) injections or sublingual immunotherapy (SLIT) tablets and is used to treat moderate-severe allergic rhinitis (AR).
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F. Pollock   +5 more
doaj   +1 more source

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Frontiers in Oncology, 2020
BackgroundEchinoderm microtubule-associated protein-like 4 (EML4) is the canonical anaplastic lymphoma kinase (ALK) fusion partner in non-small cell lung cancer (NSCLC), and ALK-positive patients showed promising responses to ALK tyrosine kinase ...
Jin Kang, Xu-Chao Zhang, Xu-Chao Zhang, Xu-Chao Zhang, Hua-Jun Chen, Wen-Zhao Zhong, Yang Xu, Jian Su, Qing Zhou, Hai-Yan Tu, Zhen Wang, Chong-Rui Xu, Xue-Ning Yang, Zhi-Hong Chen, Xue Wu, Xian Zhang, Yang Shao, Yang Shao, Yi-Long Wu, Yi-Long Wu, Jin-Ji Yang   +20 more
doaj   +1 more source

Dibenzazepin‐verbrückte Netzwerk‐Polymer‐Phthalocyanine als abbaubare heterogene Photokatalysatoren

Angewandte Chemie, EarlyView.
Photodynamische Dibenzazepin‐Brücke wurde in Zink‐ und Kobalt‐Netzwerk‐Polymer‐Phthalocyanine (NP‐Pcs) eingeführt, um abbaubare heterogene Photokatalysatoren zu erhalten. Zum ersten Mal spielt die Bestrahlung mit Licht eine Schlüsselrolle beim „Design, der Verwendung und dem Abbau” von NP‐Pcs.
Erem Ahmetali, Azra Kocaarslan, Vanessa Trouillet, Stefan Heißler, Stefan Bräse   +4 more
wiley   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Analysis of SWI Complex Subunits in 69 Cases of TTF‐1 Negative Non‐Small Cell Lung Carcinoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Non‐small cell lung carcinomas, not otherwise specified (NSCLC‐NOS) with a specific signature including high‐grade hepatoid/clear cell morphology, negative lung panel mutational analysis, negative TTF‐1/Napsin A staining can be reported as a morphologic variant of an aggressive carcinoma with loss of one of the subunits of the SWI/SNF ...
Ramin Zargham, Feng (Selina) Ji, Tarek Bismar   +2 more
wiley   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Advances in Double‐Stranded DNA Targeting Technologies

Exploration, EarlyView.
Double‐stranded DNA (dsDNA) plays a crucial role in genetic information storage and disease management, but its inherent stability limits access to internal bases. To overcome this challenge, various high‐specificity molecular targeting technologies have been developed to destabilize the DNA structure.
Zuhao Shen, Yiqun Liu, Yingjie Hao, Yifan Bo, Xiaochuan Dai, Shihui Wang, Tian Xia, Xin Su, Huiyu Liu   +8 more
wiley   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, EarlyView.
What's New? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source